Diagnosis and Treatment of Soft Tissue Tumours: The Dutch Nationwide-Accepted Consensus by Van Geel, A. N. et al.
Sarcoma (1998) 2, 183± 191
ORIGINAL ARTICLE
Diagnosis and treatment of soft tissue tumours: the Dutch
nationwide-accepted consensus
A. N. VAN GEEL,
1 J. A. M. VAN UNNIK
2 & R. B. KEUS
3
On behalf of the Dutch Cooperative Group for Soft Tissue Tumours
1Surgical Oncology, Rotterdam Cancer Institute/Daniel den Hoed Cancer Center, Rotterdam &
2Pathology, Bosch en
Duin &
3Radiotherapy, Netherlands Cancer Institute/Antoni van Leeuwenhoekhuis, Amsterdam, The Netherlands
Introduction
A reasonable number of soft tissue sarcomas are
found by chance. The reason is that general sur-
geons are not familiar with these cancers and some-
times do not realize that an `atypical lipoma’ or a
`hernia of the muscle’ could be a soft tissue sar-
coma. Whether these `whoops’ operations badly
in¯ uence the prognosis is uncertain, but it is certain
that de® nitive surgery can be very complex with
increased morbidity and frequently needed adjuvant
radiotherapy.
With this knowledge in mind, the Dutch Cooper-
ative Group for Soft Tissue Tumours, founded in
1991, recognized this important issue. The ® rst
activity involved organizing a nation-based consen-
sus meeting. To achieve this goal all cancer centres
(2), universities (6) and comprehensive cancer cen-
tres (9) were asked to send representative partici-
pants to prepare a draft report. On 29th October
1993, after two-and-a-half-years and nine meetings,
the text was open for discussion. Thereafter the
de® nitive text was sent to all surgeons and to spe-
cialists involved in soft tissue sarcoma treatment
(ISBN 90-6910-164-5). A shorter version was pub-
lished in the national general medical journal
(Ned.Tijdsch.Geneesk 1995; 139: 833± 7).
The original text is now published in this journal.
The intention is that this text, based on 28 main
questions, can be helpful to those people who are
also preparing a regional or national consensus.
Alternatively this text could be encouraging those
doctors with a special interest in soft tissue sarcoma
to prepare such a consensus.
Basic questions
1: What order in diagnostics should be followed in
patients presenting with a suspicious soft tissue
tumour?
2: What conditions can be made for the prep-
aration of pathology specimens and how to
report the results?
3: What are the therapeutic possibilities of surgery,
radiotherapy and chemotherapy in the treat-
ment of primary soft tissue sarcoma?
De® nition and classi® cation
1. Soft tissue sarcomas form a heterogeneous group of
uncommon tumours with histopathological aspects of
connective, muscle, fatty tissue or peripheral nerve tissue
Soft tissue sarcomas include non-epithelial tumours,
excluding tumours of the haematopoietic system,
lymph nodes, skeleton and central nervous system.
However, tumours of the peripheral nerve system
are classi® ed as soft tissue tumours. Contrary to
other customary classi® cations, also non-epithelial
tumours of the internal organs such as the stomach
and uterus are discussed in this consensus text,
since their diagnostics and treatment do not virtually
differ from those occurring in other sites. Paediatric
tumours (age, 16) are disregarded because of their
speci® c problems.
2. Classi® cation of soft tissue sarcomas according to
Enzinger and Weiss
1’ is currently most common
Prognosis of soft tissue sarcomas is determined by
grade of malignancy and histological typing. Over
the years many classi® cations have been proposed.
Currently, the classi® cation according to Enzinger
and Weiss is used most, comprising in short:
® brosarcoma
dermato® brosarcoma protuberans
1Soft Tissue Tumors, 2nd edition. St. Louis: C. V. Mosby, 1983, p. 13.
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malignant ® brous histiocytoma
liposarcoma
· well differentiated
· mixoid
· round cell
· pleomorphic
leiomyosarcoma
rhabdomyosarcoma
rhabdoid sarcoma
angiosarcoma
malignant haemangiopericytoma
synovial sarcoma
malignant Schwannoma
peripheral primitive neurectodermal tumour
extraskeletal chondrosarcoma
· myxoid
· mesenchymal
extraskeletal osteosarcoma
malignant granular cell tumour
alveolar soft tissue sarcoma
epitheloid cell sarcoma
clear cell sarcoma
extraskeletal Ewing’s sarcoma
It is not always possible to classify a sarcoma into
one of the above types. Such tumours are classi® ed
as `not otherwise speci® ed sarcoma’ (NOSS). This
classi® cation does not include malignant mesothe-
lioma because of its typical localization and corre-
sponding clinical behaviour, or locally aggressive
non-metastasizing tumours such as (aggressive)
® bromatosis.
Soft tissue tumours can principally occur in all
sites of the body. Most frequent localizations are:
lower extremity 40% (of which 75%
above the knee)
upper extremity 15%
chest/abdominal wall 15%
head and neck 15%
retroperitoneum 10%
Epidemiology
3. Soft tissue sarcomas are uncommon and their fre-
quency in south-east Holland has not signi® cantly
increased since 1975
According to the National Cancer Registration, soft
tissue sarcomas comprised , 1% of all new malig-
nancies in The Netherlands in 1989 and 1990. In a
total of 55,000 new cancer patients per year, 691
patients were diagnosed with sarcoma, of whom 364
had a soft tissue sarcoma. Incidence rates were 2.7
in males and 2.1 in females per 100,000 per year.
According to a special documentation by the IKMN
(Comprehensive Cancer Centre for central Hol-
land) cancer registration, apart from these 364
patients, another 90 patients (25%) had a low
malignant tumour included in the policy discussed
here.
The long-term cancer registration by the IKZ
(Comprehensive Cancer Centre for South Holland)
in Eindhoven shows no increase in the incidence of
soft tissue sarcomas; however, it does show a
signi® cant increase in the number of small tumours
and a decrease in the percentage of larger tumours
of unknown size.
Diagnostics
4. Recognize an uncommon tumour!
In a patient suspected of having a soft tissue
tumour, a sarcoma should be assumed until proof to
the contrary; assessment of complaints and growth
speed and of local tumour growth, and regional and
distant metastases is necessary, including accurate
assessment of tumour size (in cm) and involvement
of surrounding structures. A fast-growing tumour
(i.e. in some weeks to months) or a tumour situated
under the deep fascia should suggest a strong sus-
picion of a malignancy. A solid consistency and an
unusual localization should also alarm the clinician.
In case of the slightest suspicion of a malignancy,
surgical exploration of a soft tissue tumour should
adhere to a number of rules. The prognosis of soft
tissue sarcomas at presentation depends on two
factors only: local tumour extension (local and/or
distant metastasis), and the biological behaviour of
the tumour, expressed as `grade of malignancy’. The
latter prognostic factor cannot be in¯ uenced; how-
ever, previous inexperienced manipulation can
indeed unfavourably in¯ uence the ® rst, hence com-
plicating de® nitive treatment. Contamination of
nearby muscle groups or compartments by invasive
examination necessitates involvement in the
de® nitive treatment. Therefore, it is highly recom-
mended that diagnostic imaging (for localization
and staging) is performed prior to invasive diagnos-
tics and particularly prior to biopsy.
5. Diagnostic imaging before every invasive examin-
ation
Imaging techniques that can be used are: conven-
tional X-rays, ultrasound (us), MRI and/or CT.
Bone scintigraphy and arteriography are not indi-
cated, except in special situations that cannot be
included in a protocol. Only in exceptional cases can
a probability diagnosis based on diagnostic imaging
be made. Usually diagnostics start with conventional
X-rays that can give an impression of the extension
of the tumour and of skeletal involvement. It can
often differentiate the diagnosis of a primary soft
tissue process between a primary osteosarcoma or a
soft tissue tumour with skeletal in® ltration (e.g. in
synovial sarcoma). Vascular calci® cations may indi-
cate haemangioma. Ultrasound is a low-cost, fast
and non-invasive method to get a ® rst impression of
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diagnosed tumour. Sometimes the nature of the
tumour can be further de® ned.
6. MRI is the most reliable method to assess localization
and size of a soft tissue tumour, as well as involvement
in several anatomical compartments
Magnetic resonance imaging (MRI) is a most
reliable method to de® ne exactly the localization
and macroscopic extension of the tumour. Not only
tumour size, but also involvement in several
anatomical compartments (muscle groups, cortex,
bone marrow, neurovascular bundle, joint) can be
accurately assessed. It is possible to identify the
tumour, the pseudocapsule and the reactive zone.
Since tru-cut and surgical (open) biopsies cause
reactive changes that are dif® cult to differentiate
from tumour tissue by MRI. MRI should be per-
formed prior to these invasive procedures. At least
two T1 and T2 weighed perpendicular MRIs (e.g.
in the transversal and sagittal directions) should be
made.
CT is less reliable than MRI. CT is preferred in
instances of an intra-abdominal tumour, such as
leiomyosarcoma of the stomach. In tumours orig-
inating from muscle and connective tissue, etc. CT
is only indicated when MRI cannot be realized
because of compelling practical or patient-related
reasons (claustrophobia, pacemaker, eye lens
implant).
In a number of cases, particularly benign diseases,
a speci® c diagnosis can be made by MRI.
7. Since soft tissue sarcoma in general metastasizes
primarily to the lung, screening for lung metastases is a
routine procedure in all patients with a soft tissue sar-
coma
For lung screening, conventional X-rays and CT-
thorax are used. Timing of X-thorax is not critical.
It can be performed at the start of analysis (in case
of a strong clinical suspicion), or alternatively after
histologically diagnosing a soft tissue tumour. CT is
indicated when histology shows a malignant
tumour, whereas X-thorax does not indicate the
presence of lung metastases.
8. Cytology is valuable in assessing a recurrent soft
tissue tumour
Cytology is not the ® rst choice to diagnose a soft
tissue tumour. When differentiation of a primary
tumour between a soft tissue tumour, an epithelial
tumour, a melanoma or a lymphoma is suf® cient,
cytology can generally be conclusive. In tumours
surgically dif® cult to access, an ultrasound-guided
cytological biopsy can be taken. The biopsy site
should be marked. Cytological examination by a ® ne
needle biopsy can be useful to assess recurrence or
metastasis of a known sarcoma. A tru-cut biopsy is
indicated in tumours for which a cytological biopsy
is inconclusive. For tissue obtained by tru-cut
biopsy only a limited histopathological classi® cation
and/or staging can be assessed. By performing a
tru-cut biopsy, a tissue cylinder is obtained directly
from the tumour periphery, hence avoiding non-
involved muscle groups. Specimens obtained from
the tumour centre often yield necrosis. The biopsy
site is sutured; the suture remains in situ until
de® nitive treatment.
9. Also an incisional biopsy is aimed at a combined
treatment of surgery and radiotherapy without unneces-
sary mutilation
Except in small super® cial tumours the aim of surgi-
cal exploration should be kept in mind: to obtain
histopathological material and not to be a de® nitive
treatment for soft tissue sarcoma.
In performing an incisional biopsy, the following
guidelines should be followed:
· avoid contamination of other muscles/muscle
groups or compartments as a result of
in® ltration anaesthesia, tumour manipu-
lation, haematoma and infection;
· perform the biopsy by a longitudinal incision;
· do not undermine skin margins;
· take the biopsy from the tumour periphery
(including the pseudo-capsule);
· wash the wound with cytolytic ¯ uid (sterile
water, Dakin-¯ uid);
· perform accurate haemostasis;
· when using a drain, do not release this
through a separate drain hole;
· use sterile instruments when closing the
wound;
· send fresh specimens to pathology (eventu-
ally frozen sections, re: `representative
material?’).
10. Send fresh soft tissue tumour specimens to pathol-
ogy, indicating margins, growth speed and previous
treatment
In requesting a pathology review, the following
should be speci® cally recorded:
· tumour localization (super® cial or deep) and
in case of a biopsy, biopsy specimen or partial
resection, and tumour sizes;
· recurrence: yes or no;
· previous treatment (if applicable).
The resected tumour should be intact and fresh
when handed to the pathologist. Surgical adequacy
can then be judged best and before total ® xation
tumour fragments can be removed for freezing pur-
poses and separate ® xation for EM and other tests.186 A. N. van Geel et al.
11. Pathology review is aimed at assessing a de® nitive,
classifying diagnosis and at determining the extension of
the soft tissue tumour, the extent of surgical adequacy in
case of a malignancy, and prognostic factors in¯ uencing
treatment
Pathology reviews and reports should include the
following:
· surgical nature (incisional biopsy, excisional
biopsy, radical resection, etc.);
· tumour sizes, preferably in three dimensions,
but minimally mentioning the largest diameter;
· surrounding tissues and involvement with the
tumour (in® ltration: yes or no): skin, fascia,
muscle, fatty tissue, nerve, bone;
· relation between the tumour and the resec-
tion lines, particularly the possible presence
of macroscopic disease in this area. Marks
applied by the surgeon to reconstruct the
original position of the tumour in the body
should be used here. Resection lines should
be marked, e.g. with Indian ink;
· thickness of the cuff of normal tissue sur-
rounding the tumour, with special attention
for those sites indicated as non-radical resec-
tions (because of technical dif® culty). Muscle
retraction can hinder judgement of treatment
adequacy. It is very useful and sometimes
necessary that the pathologist examines the
macroscopic specimen together with the sur-
geon. The conclusions of this joint examin-
ation should be recorded in writing
(schematic drawing!);
· tumour consistency and shape (clear mar-
gins: yes or no; nodular), as well as its aspect
in diameter, especially colour, and presence
and extension of myxoid parts and necrosis;
· non-radical resections based on macroscopic
observations and the marks applied by the
surgeon. Fractions of these areas should be
prepared as well and should be ® led such,
preferably based on a schematic drawing, that
their origin can be reconstructed. For micro-
scopic diagnosis of the nature of the tumour
a suf® cient number of tissue specimens
should be removed as well. As a guideline
two fractions will be suf® cient for a tumour
with maximum diameter up to 5 cm; a
tumour . 5 cm will need the number of frac-
tions corresponding to half of the largest
diameter in centimetres. It is not particularly
useful to prepare fractions from completely
necrotic areas. However, necrosis should be
microscopically assessed. Particularly, frac-
tions should be prepared fromÐ macroscopi-
cally describedÐ areas with a deviating aspect;
· grading;
· the conclusion should minimally include the
following:
(i) surgical nature
(ii) localization
(iii) previous treatment (if applicable)
(iv) histological typing and grade
(v) tumour size(s)
(vi) data on treatment adequacy
12. Classi® cation in grades of malignancy and classify-
ing diagnosis are equally important for soft tissue sar-
coma prognosis
To de® ne prognostic correlations, grading and his-
tological typing of soft tissue sarcoma are equally
important. Most publications appear to acknowl-
edge prognostic value to histological typing, but in
general this value disappears when in a multivariate
analysis histological typing is tested as a variable
next to grading.
In this context it is striking that a generally
accepted system exists for histologically typing these
sarcomas, but not (as yet) for grading these malig-
nancies. From recent analysis it appears time and
again that by multivariate analysis the number of
mitoses, and the presence and amount of necrosis
are decisive for prognosis. This also appears from a
recently published EORTC study on which the fol-
lowing classi® cation is based:
· grade 1: , 4 mitoses per 2 mm
2
· grade 2: 4± 25 mitoses per 2 mm
2
· grade 3: . 25 mitoses per 2 mm
2
In tumours that can locally be treated adequately, a
5-year survival can be expected for over 90% of
grade 1 tumours, 6 70% for grade 2 tumours and
6 45% for grade 3 tumours. We may assume that
this system includes malignant ® brous histiocytoma
(MFH), liposarcoma, leiomyosarcoma, ® bro-
sarcoma, malignant Schwannoma, and synovial
sarcoma, together comprising . 86% of diagnosed
sarcomas. In other sarcomas the grade of malig-
nancy should be estimated based on histological
typing. This grading system excludes sarcomas of
the internal organs. In the study on which this
system is based, the presence or absence of necrosis
merely renders the possibility to divide grade/score 3
tumours into two additional grades. In practice, no
need appears to do this.
NB: the number of mitoses cannot simply be used
to differentiate between a benign (i.e. reactive) and
a malignant mesenchymal proliferation. Benign
mesenchymal proliferations exist with a large num-
ber of mitoses.
13. Aggressive ® bromatosis and similar tumours are
treated as locally malignant
Apart from sarcomas and benign tumours with only
limited growth potential, a group of soft tissue
tumours can be distinguished with unlimited growth
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tumours can be classi® ed as `locally malignant’.
Recurrence is due after inadequate local treatment.
Since surgical treatment of a recurrence generally is
more extensive and more mutilating, adequate local
treatment is indicated ® rst.
For another group of tumours, histopathology
cannot predict their clinical behaviour (such as
probability of recurrence). This group is termed
`tumours of intermediate malignancy’ (according to
Enzinger and Weiss). In these tumours the extent of
surgery depends on considering both the disadvan-
tages of locally adequate treatment and the possibil-
ity of adequately treating a recurrence.
Treatment
14. Soft tissue sarcoma requires multidisciplinary treat-
ment from the start. The team are acquainted with each
other’s diagnostic and therapeutic possibilities
Surgery is the ® rst line of treatment for soft tissue
tumours. Conditions for proper surgical treatment
are:
· pre-operative staging (cTNM);
· pre-operative review with the consultant
representing the hospital’s Oncology Work-
ing Party (Comprehensive Cancer Centre);
· preferably pre-operative assessment by a
radiation oncologist;
· preferably one adequate operation;
· marking of areas at risk and narrow margins
with titanium staples.
15. Direct primary excision only indicated for small
super® cial soft tissue tumours
Primary resection (excisional biopsy) should only be
considered for very small (, 3 cm) super® cial
tumours, for which surgery will not render func-
tional loss. As in resection, also for these primary
resections, wide margins are required.
Radical resection is resection of the tumour en bloc
including a cuff of normal tissue of at least 2 cm.
For tumours in® ltrating muscular compartments
compartmental resection may be considered.
If radical resection implies sacri® cing the neu-
rovascular bundle or bone, causing severe morbid-
ity, a combined treatment of surgery and
radiotherapy is preferred.
For retroperitoneal or head and neck lesions,
radical resection will often be impossible for
anatomical reasons. A less radical resection and
post-operative radiation will be the treatment of
choice.
16. Surgical reports should completely describe all con-
clusions, anatomical structures and areas at risk
The surgical report should include the following:
· operation, approach and vital structures;
· a schematic drawing of the resection, particu-
larly indicating margins and anatomical
structures;
· areas at risk (narrow margins);
· haemoclips used as landmarks;
· size of the tumour in centimetres;
· reconstruction.
17. Inadequate surgery is preferably followed by reoper-
ation, after consulting the Oncology Group
In case of inadequate resection, when clearance
margins show evidence of residual macroscopic
tumour (according to the surgical report/pathology
conclusions), re-resection of the entire contami-
nated area should be performed if possible. If re-
resection is not possible, radiotherapy should be
applied.
18. Retroperitoneal sarcoma should be treated by a
properly prepared radical resection, if possible followed by
radiation to the tumour bed
Because of anatomical reasons, radical resection
sometimes implies resection of surrounding struc-
tures as well, such as the colon, ureter, iliacal
vessels, etc., with optional reconstruction. Pre-
operative review with the specialists in charge is
strongly recommended. Margins often appear to be
inadequate still. Therefore, treatment principally
requires a combined planning of surgery and radio-
therapy.
19. After surgical treatment of retroperitoneal sarcoma
the use of the omentum or a spacer should be considered
to prevent radiation damage
To apply a suf® cient radiation dose to the original
tumour volume, precautions should be taken to
prevent irreversible small bowel radiation damage, a
long-term complication. One of these precautions is
retraction of the small bowel from the surgical area.
20. Radiotherapy is indicated after planned non-radical
resection, when the resection margin is , 1 cm after
® xation, or after incomplete resection of the original
surgical area
The development of megavoltage radiation equip-
ment and modern radiation techniques enables
accurate radiation, hence sparing surrounding nor-
mal tissues. In patients with a limited tumour pro-
cess, post-operative adjuvant radiotherapy appears
to reduce the risk of a local recurrence.
In this combined treatment radiotherapy can be
performed pre-operatively or post-operatively. Post-
operative radiotherapy has been applied most. The
advantages of post-operative radiation over pre-
operative radiation are:188 A. N. van Geel et al.
· no delay of surgery;
· no increased risk of post-operative complica-
tions;
· optimal information on the extent, margins
and histological aspects of the tumour, to
determine the treatment volume;
· the radiation oncologist can inform himself of
the exact tumour extent during surgery.
Post-operative radiotherapy is indicated for all G3
tumours and recurrences, even after radical surgery.
In all other cases post-operative radiotherapy is indi-
cated by the result of surgery:
· after non-radical surgery, when reoperation is
impossible or too mutilating;
· after reoperation because of non-radical
surgery, when the entire surgical area has not
been removed;
· after marginal radical surgery (margin , 2
cm [fresh specimen] or , 1 cm [after
® xation]);
· in case of tumour contamination (`spill’) dur-
ing surgery.
The target area for post-operative radiotherapy
includes the entire original tumour volume, possible
microscopic extension and areas possibly contami-
nated during resection (drain, haematoma). To
determine the target area a complete description of
the surgical procedure and the pathology report, as
well as pre-operative CT and/or MRI scans should
be available to the radiation oncologist. Radiation
margins depend on tumour localization and extent.
Guidelines for determining the target area are:
· In intracompartmental tumours, the related
compartment is considered the target area.
· Margins for extracompartmental high-grade
tumours (grades 2 and 3) are 7± 10 cm longi-
tudinally from the original tumour, taking
natural margins into account. For low-grade
tumours the margin can be 5 cm. Margins
should be wide, particularly in the direction
of vessels and nerves and of fascia and muscle
® bers. Transversely, a margin of at least 2 cm
can be chosen, again taking into account
natural margins of anatomical structures.
· In subcutaneous tumours not in® ltrating the
fascia and not situated near vessels and
nerves, a margin of 5 cm around the original
tumour will be suf® cient.
· For the booster dose the target area is the
original tumour bed with a margin of 2 cm.
After a non-radical resection the highest dose
is applied to an area that is preferably marked
during surgery. The margin is determined by
the treatment volume, the total dose, and
normal tissue tolerance.
Radiation is generally performed using multiple
megavoltage photon beams. A CT-scan in radiation
position can be used to determine the treatment
plan and to calculate the dose distribution. In case
of radiotherapy of an extremity, beam directions
should be chosen sparing non-affected muscle com-
partments and bone as much as possible. The
interosseous membrane of the distal limb can serve
as the margin between the irradiated and the non-
irradiated part of the extremity. Radiotherapy to the
entire limb periphery should be avoided as much as
possible to preserve lymph drainage. Haemoclips
placed in the bottom and at the margins of the
surgical area can be useful to determine the treat-
ment volume. Patient positioning reproducibility
may bene® t from proper patient ® xation in radiation
position. To this end, several methods are available.
Radiotherapy to retroperitoneal or abdominal sites
may be dif® cult due to surrounding radiosensitive
organs such as kidneys and bowel. Placing a spacer
(either a tissue expander ® lled with saline or a
silicone breast prosthesis) or a pedicled omento-
plasty between the treatment volume and these
organs enables application of a higher radiation dos-
age.
ICRU dose recommendations are 50 Gy in 25
fractions in 5 weeks to the above treatment volume,
plus 10 Gy in 5 fractions applied similarly to the
original tumour volume, including the above-men-
tioned margins.
21. Post-operative interstitial radiotherapy enables more
accurate determination of the booster area and sparing of
healthy tissues
When surgery is performed in a hospital with
brachytherapy facilities, the radiation oncologist
can, immediately following excision, insert loops in
the original tumour area for post-operative inter-
stitial application of an iridium booster dose using
an afterloading system. This approach requires
intensive consultation between the surgeon and the
radiation oncologist before the start of treatment.
Preferably, the patient is also assessed by the radi-
ation oncologist before treatment. Technique and
dose of interstitial radiotherapy are presently stud-
ied.
22. During radiotherapy to an extremity and at least
during 1 year thereafter physiotherapy is prescribed to
prevent contractures
After high-dose radiotherapy some ® brosis and skin
discolouration is often seen. Severe complications
after radiotherapy may be: function impairment due
to ® brosis of muscles and subcutaneous tissues;
joint ankylosis; lymph oedema; and vascular
insuf® ciency due to vascular damage. Also bone
fractures due to irradiation are seen until long after
treatment.
Accurate assessment of the radiation technique
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decreases the risk of these complications. After a
combined treatment of surgery and radiotherapy,
long-term physiotherapy is highly important to pre-
serve extremity function. These exercises, aimed at
keeping muscles and tendons at full length, should
be done under the guidance of a physiotherapist and
preferably after consulting a rehabilitation physician.
They should be started prior to and during radio-
therapy and be maintained for 1± 2 years after treat-
ment.
23 Chemotherapy for primary and metastasized soft
tissue sarcoma is experimentally administered in trials
Only three cytostatic drugs have proved to be effec-
tive in soft tissue sarcoma (adriamycin, ifosfamide
and, to a lesser extent, DTIC). Dose± effect rela-
tions, combined treatment schedules and the
addition of growth factors are currently under inves-
tigation. Systemic therapy is applied in trials only.
Adjuvant chemotherapy in high-risk patients is not
indicated as yet. The value of chemotherapy prior to
radical surgery has not been assessed yet, nor when
administered intra-arterially in extremity lesions.
Induction (neo-adjuvant) chemotherapy is adminis-
tered in trials only.
24. Prior to resection of lung metastases a number of
terms have to be met: (i) the primary tumour should be
under control; (ii) exclusion of extrapulmonary metas-
tases; (iii) no contraindications for pulmonary surgery
Soft tissue sarcoma usually metastasizes primarily to
the lungs. Therefore, all patients with soft tissue
sarcoma should be examined for lung metastases.
Since diagnosing lung metastases is clinically rel-
evant, chest X-ray is performed ® rst. A negative
chest X-ray does not rule out lung metastases and a
CT-thorax should follow. Radical surgery of lung
metastases can accomplish cure or long-term com-
plete remission. Lung function is extremely import-
ant in patients who had previous chemotherapy.
There should be no contraindications for pulmonary
surgery.
Adequate patient selection can render a 5-year
survival of 30± 40%. One factor is of utmost import-
ance: radical metastectomy should be feasible. Prog-
nosis after radical metastectomy in grade 3 tumours
seems less favourable than in grade 1 and grade 2
tumours.
The choice between a sternotomy and a unilateral
or bilateral thoracotomy strongly depends on local-
ization and the number of metastases.
25. Embryonal soft tissue sarcomas in adults are treated
as paediatric tumours
Although the available separate studies do not show
this numerically, analysis of a large number of pub-
lications using chemotherapy (doxorubicin 1 DTIC,
or this combination plus supplementary endoxan
and vincristin) shows no difference in response to
chemotherapy in several histological types of soft
tissue sarcoma. Embryonal rhabdomyosarcoma in
adults is an exception. The clinical behaviour of this
subtype is somewhat different: rather fast-growing,
extensive haematogenic metastasis and a striking
sensitivity to chemotherapy. Whereas chemotherapy
for other histological subtypes renders response rates
of 20± 40%, the response rates of embryonal rhab-
domyosarcoma to chemotherapy is 80± 90%. In gen-
eral, drugs such as vincristine and actinomycin have
little effect on soft tissue sarcoma. However, these
drugs do appear to be effective in embryonal rhab-
domyosarcoma. Based on these data, it is recom-
mended to treat embryonal rhabdomyosarcoma
analogous to paediatric tumours with chemotherapy,
such as Ewing’s sarcoma and nephroblastoma.
26. If resection of a soft tissue sarcoma of the limb leads
to amputation or severe morbidity, an isolated regional
perfusion using TNF-a should be considered
Regional isolated perfusion has been used as an
alternative to amputation. This method enables
regional administration of high doses of chemo-
therapy in soft tissue sarcoma of the limbs without
the risk of (lethal) toxicity. However, despite the use
of different regimes the results are disappointing
regarding the choice of cytostatics as well as the
application of hyperthermia.
Tumour Necrosis Factor-a (TNF-a ) is a cytokine
with an acute and dramatic anti-tumour effect in
animal tumour models. Effective doses in animals
are many times (. 20 3 ) higher than the maximum
allowed dose in humans. Systemic administration of
TNF-a in humans causes severe toxicity without
reaching a signi® cant anti-tumour effect. Effective
TNF-a levels can be reached in isolated regional
perfusion of the limbs.
The anti-tumour effect of TNF-a is probably
based predominantly on selective total destruction
of tumour vessels. This is illustrated by pre- and
post-perfusion angiographies, as well as by histo-
pathological ® ndings. Melfalan has a strongly syner-
gistic effect in combination with TNF-a . The
tumours usually react with acute softening, as an
expression of massive necrosis, followed by tumour
regression, hence turning the tumour mobile and
resectable.
In a multi-centre TNF study in Rotterdam
(DDHCC), Groningen (University Hospital),
Amsterdam (Antoni van Leeuwenhoek Hospital)
and Lausanne (Centre Pluriforme d’Oncologie)
patients with an irresectable soft tissue sarcoma of
the limb are treated.
An anatomical or functional amputation can be
prevented in 6 90% of the patients by performing
an isolated perfusion, followed by a generally minor
resection of tumour remnants, instead of ampu-190 A. N. van Geel et al.
tation or a mutilating combination of major resec-
tion and radiotherapy.
Response percentages of soft tissue tumours to
TNF perfusion are impressive: CR 44%, PR 53%
and SD 3%. However, it has not (yet) rendered a
bene® t in survival.
27. All patients with soft tissue tumours are preferably
treated in trials
Soft tissue tumours are uncommon tumours with a
large scale in histology and grading. Adequate local
treatment reduces the risk of local recurrence to
10± 20%; however, 40% of patients with soft tissue
tumours will develop distant metastases.
In order to get more insight in all tumours and to
improve the prognosis of patients with soft tissue
tumours, it is essential to participate in trials.
28. Rarity and diversity of soft tissue sarcoma and the
uncertainties and complexity of the treatment argue for a
national approach in documenting diagnostics, staging
and treatment
Soft tissue sarcoma rarity is shown by the fact that
the average surgeon and a pathologist see a few new
cases only once every 2 years and once a year,
respectively. Moreover, there is a diversity in local-
izations (for the surgeon) and in histological typing
(for the pathologist).
National documentation in this ® eld gives a
unique opportunity to acquire a better insight into
the behaviour, diagnostics and treatment of these
tumours. Large-scale studies have until now exclu-
sively been performed in centres meeting a selection
of patients. It is of utmost importance to start a
larger databank than the current one used for cancer
registration. Before ® ling the data, the main ques-
tions related to these tumours should be considered.
Appendix 1
Follow-up
Follow-up should be aimed at:
1. control of (functional) recovery after treatment
2. recognition of a local recurrence
3. recognition of (a) lung metastasis (metastases)
4. recognition of late complications
Frequency of follow-up
1st and 2nd year: every 3 months
3rd, 4th and 5th year: every 6 months
. 5 years: once per year
After 10-year disease-
free survival: stop follow-up
Contents of follow-up
Always: historyÐ general and
speci® c physical examin-
ation
Every 6 months
during the ® rst 2 years: CXR/yearly thereafter
When indicated: CT-scan or MRI
Indications for CT or MRI may be:
· determining post-operative starting point in
tumour areas dif® cult to examine, e.g.
(i) sarcomas of the head and neck
(ii) retroperitoneal sarcomas
(iii) sarcomas of pelvis and hip
· follow-up of local control after doubtful rad-
ical surgery
· in case of complaints or clinical suspicion.
Appendix 2
TNM classi® cation (UICC 1992, adults)
The TNM (Tumour, Node, Metastasis)
classi® cation is exclusively used in adults (minimal
age 16 years) and for histologically proven sarcomas.
Minimally required procedures for assessing the T
category: physical examination and imaging (MRI or
CT-scan and/or ultrasound) of the primary tumour:
T 5 Primary tumour
Tx 5 Primary tumour cannot be assessed
T0 5 No evidence of primary tumour
T1 5 Tumour diameter 5 cm or less
T2 5 Tumour diameter . 5 cm
Minimally required procedures for assessing the
N category: physical examination:
N 5 Regional lymph nodes
Nx 5 Regional lymph nodes cannot be assessed
N0 5 No regional lymph node metastasis
N1 5 Regional lymph node metastasis
Minimally required procedures for assessing the
M category: physical examination, laboratory exami-
nations and chest X-ray (if necessary, CT-thorax):
M 5 Distant metastasis
References
Brant TA, Parsons JT, Marcus RB, et al. Irradiation for
soft tissue sarcomas of the trunk and extremities in
adults. Int J Radiat Oncol Biol Phys 1990; 19; 899± 906.
Carson AG, Putman JB, Natarjan G, et al. Five year
survival after pulmonary metastasectomy for adult soft
tissue sarcoma. Cancer 1992; 69; 662± 8.
Cionini L, Marzano S, Olmi P. Soft tissue sarcomas:
experience with intraoperative brachytherapy in the
conservative management. Ann Oncol 1992; 3 (Suppl.
2); S63± S66.
Collin C, Godbold J, Brennan M. Localized extremityDutch consensus on soft tissue tumours 191
soft tissue sarcoma: an analysis of factors affecting
survival. J Clin Oncol 1987; 5; 601± 12.
Elias AD, Curtman H. Adjuvant chemotherapy for soft
tissue sarcoma: an approach in search of an effective
regime. Scm Oncol 1989; 16; 305± 11.
Enzinger FM, Weiss SW. Soft tissue tumours. St. Louis
[etc.]: Mosby 1988. Guiliano AE, Eilber FR. The
rationale for planned re-operation after unplanned total
excision of soft tissue sarcomas. J Clin Oncol 1985;
3; 1344± 8.
Habrand JL, Gerbaulet A, Pejovic MH, Contesso G,
Durand S, Haie C, et al. Twenty years experience of
interstitial iridium brachytherapy in the management of
soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1991;
20; 405± 11.
Kransdorf MJ. Jelinek IS, Moser RP. Imaging of soft
tissue tumors. Radiologic Clin N Am 1993; 31; 359± 72.
Lienard D, Lejeune FJ, Delmotte JJ, Renard N, Ewalenko
D. High doses of rTNF-a in combination with IFN-
gamma and melphalan in isolated perfusion of the limbs
for melanoma and sarcoma. J Clin Oncol 1992; 10; 52±
60.
Markhede G, Angervall L, Stener B. A multivariate analy-
sis of the prognosis after surgical treatment of malignant
soft tissue tumours. Cancer 1982; 49; 1721± 33.
Martini N, McCormack PM. Pulmonary resection in
sarcoma metastases. In: Ryan JR ed.: Recent concepts in
sarcoma treatment. Dordrecht: Kluwer, 1988; 197± 200.
Mills EED, Hering ER. Management of soft tissue
tumours by limited surgery combined with tumour bed
irradiation using brachytherapy and supplementary tele-
therapy. B J Radiol 1981; 54; 312± 7.
Mankin HJ, Lange TA. Spanier SS. The hazards of biopsy
in patients with malignant primary bone and soft tissue
tumors. J Bone Joint Surg 1982; 64A; 1121± 7.
Russell WO, Cohen J, Enzinger FM. et al. A clinical and
pathological staging system for soft tissue sarcoma.
Cancer 1977; 40; 1562.
Rydholm A. Berg NO, Persson BM et al. Treatment of
soft tissue sarcoma should be centralized. Acta Orthop
Scand 1983; 54; 333± 9.
Shiu MH, Brennan MF. Surgical management of soft tissue
sarcoma. Philadelphia/London: Lea and Febiger, 1989.
Shiu MH, Hilaris BS, Harrison LB, Brennan MF.
Brachytherapy and function-saving resection of soft tis-
sue sarcoma arising in the limb. Int J Radiat Oncol Biol
Phys 1991; 21; 1485± 92.
Steward WP, Verwey I, Somers R, et al. Granlocyte
macrophage colony-stimulating factor allows safe
escala-tion of dose-intensity of chemotherapy in
metastatic adult soft tissue sarcomas: a study of the
EORTC soft tissue and bone sarcoma group. J Clin
Oncol 1993; 11; 15± 21.
Stinson SF, DeLaney TF, Greenberg J, et al. Acute and
long-term effects on limb function of combined modal-
ity limbsparing therapy for extremity soft tissue sar-
coma. Int J Radiat Oncol Biol Phys 1991; 21; 1493± 9.
Suit HD, Mankin HJ, Wood WC, et al. Preoperative,
intraoperative and postoperative radiation in the treat-
ment of soft tissue sarcoma. Cancer 1985; 55; 2659± 67.
Tepper J, Rosenberg SA, Glatstein E. Radiation therapy
technique in soft tissue sarcomas of the extremityÐ poli-
cies of treatment at the National Cancer Institute. Int J
Radiat Oncol Biol Phys 1982; 8; 263± 73.
Unnik JAM van, Coindre JM, Contesso G, Albus-Lutter
ChE, Schiodt T, Garcia-Miralles T, et al. A Grading of
soft tissue sarcomas: experience of the EORTC soft
tissue and bone sarcoma group. Euro J Cancer 1993;
29A; 2089± 93.